Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.

Front Endocrinol (Lausanne) · 2023 · PMC10656675 · PMID 38027199

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

biochemical markers growth hormone IGF-I therapy treatment response acromegaly Several studies have shown there may be significant improvements in specific comorbidities such as diabetes in patients who have a substantial reduction in IGF-I, even though the IGF-I value remains above the normal range ( 39 , 66 , 68 – 72 ).

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.